Back

Microbial GWAS studies revealing combinations of Omicron RBD mutations existed and may contribute to antibody evasion and ACE2 binding

Ou, X.; Yang, Z.; Zhu, D.; Mao, S.; Wang, M.; Jia, R.; Chen, S.; Liu, M.; Yang, Q.; Wu, Y.; Zhao, X.; Zhang, S.; Huang, J.; Gao, Q.; Liu, Y.; Zhang, L.; Peppelenbosch, M.; Pan, Q.; Cheng, A.-c.

2022-01-21 public and global health
10.1101/2022.01.19.22269510 medRxiv
Show abstract

Since Omicron variant of SARS-CoV-2 was first detected in South Africa (SA), it has now dominated in United Kingdom (UK) of Europe and United State (USA) of North America. A prominent feature of this variant is the gathering of spike protein mutations, in particularly at the receptor binding domain (RBD). These RBD mutations essentially contribute to antibody resistance of current immune approaches. During global spillover, combinations of RBD mutations may exist and synergistically contribute to antibody resistance in fact. Using three geographic-stratified genome wide association studies (GWAS), we observed that RBD combinations exhibited a geographic pattern and genetical associated, such as five common mutations in both UK and USA Omicron, six or two specific mutations in UK or USA Omicron. Although the UK specific RBD mutations can be further classified into two separated sub-groups of combination based on linkage disequilibrium analysis. Functional analysis indicated that the common RBD combinations (fold change, -11.59) alongside UK or USA specific mutations significantly reduced neutralization (fold change, -38.72, -18.11). As RBD overlaps with angiotensin converting enzyme 2(ACE2) binding motif, protein-protein contact analysis indicated that the common RBD mutations enhanced ACE2 binding accessibility and were further strengthened by UK or USA-specific RBD mutations. Spatiotemporal evolution analysis indicated that UK-specific RBD mutations largely contribute to global spillover. Collectively, we have provided genetic evidence of RBD combinations and estimated their effects on antibody evasion and ACE2 binding accessibility.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
National Science Review
21 papers in training set
Top 0.1%
18.1%
2
Cell Research
51 papers in training set
Top 0.1%
12.2%
3
eLife
5828 papers in training set
Top 14%
7.7%
4
Cell Discovery
57 papers in training set
Top 0.1%
5.4%
5
Emerging Microbes & Infections
74 papers in training set
Top 0.2%
4.3%
6
eBioMedicine
183 papers in training set
Top 0.6%
4.2%
50% of probability mass above
7
Cell Host & Microbe
116 papers in training set
Top 0.5%
4.0%
8
Nature Communications
5641 papers in training set
Top 34%
3.4%
9
The Lancet Infectious Diseases
73 papers in training set
Top 0.4%
3.4%
10
iScience
1154 papers in training set
Top 6%
3.4%
11
The Lancet Regional Health - Western Pacific
15 papers in training set
Top 0.1%
2.7%
12
Frontiers in Public Health
148 papers in training set
Top 2%
2.6%
13
Frontiers in Medicine
120 papers in training set
Top 2%
1.7%
14
Protein & Cell
25 papers in training set
Top 0.2%
1.7%
15
Journal of Medical Virology
140 papers in training set
Top 2%
1.7%
16
The Innovation
13 papers in training set
Top 0.1%
1.5%
17
Cell Reports
1498 papers in training set
Top 22%
1.3%
18
Med
39 papers in training set
Top 0.4%
1.1%
19
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 36%
1.1%
20
Microbiology Spectrum
469 papers in training set
Top 9%
1.1%
21
Genome Medicine
183 papers in training set
Top 4%
1.1%
22
Cell Reports Medicine
153 papers in training set
Top 3%
1.1%
23
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.6%
1.0%
24
mBio
833 papers in training set
Top 10%
1.0%
25
Science Advances
1243 papers in training set
Top 31%
0.8%
26
Allergy
25 papers in training set
Top 0.4%
0.8%
27
BMC Medical Genomics
50 papers in training set
Top 1%
0.8%
28
PNAS Nexus
159 papers in training set
Top 5%
0.6%
29
Scientific Reports
3612 papers in training set
Top 79%
0.6%